Enhabit Inc. (EHAB)vsEli Lilly and Company (LLY)
EHAB
Enhabit Inc.
$13.80
+0.07%
HEALTHCARE · Cap: $706.91M
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 6685% more annual revenue ($72.25B vs $1.06B). LLY leads profitability with a 35.0% profit margin vs -0.3%. LLY earns a higher WallStSmart Score of 76/100 (B+).
EHAB
Hold39
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
1.9% revenue growth
2.9% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : EHAB
The strongest argument for EHAB centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : EHAB
The primary concerns for EHAB are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
EHAB profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
EHAB carries more volatility with a beta of 0.96 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 39/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enhabit Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Enhabit, Inc. provides home health and hospice services in the United States.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?